Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma

Abstract

Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with a poor prognosis. The International Prognostic Index (IPI) and the Prognostic Index for PTCL‐unspecified (PIT) is used to predict the prognosis of PTCL. The hemoglobin‐platelet index (HPI), based on anemia and thrombocytopenia status, is associated with the prognosis of diffuse large B‐cell lymphoma. However, its significance in terms of predicting the prognosis of PTCL has not been fully investigated. We herein retrospectively analyzed 100 patients with newly diagnosed PTCL in our department. At a median follow‐up of 3.2 years, the median progression‐free survival (PFS) and overall survival (OS) was 0.72 (95% confidence interval [CI]: 0.56–1.2) years and 2.0 (95% CI: 1.5–4.7) years, respectively. Multivariate analysis revealed that elevated lactic dehydrogenase (LDH) and hypoalbuminemia were independent adverse variables for PFS. The HPI showed significant predictive value for both PFS and OS. As a new prognostic model comprising the HPI, LDH, and albumin, the LA‐HPI allowed the stratification of patients into four distinct risk subgroups: low risk (zero risk factors), low‐intermediate risk (one risk factors), high‐intermediate risk (two or three risk factors), or high risk (four risk factors). The PFS and OS differed significantly among the patients by the LA‐HPI score. The LA‐HPI demonstrated better predictive performance compared to the IPI, PIT, and HPI. Our data demonstrated the prognostic utility of the HPI in patients with PTCL. The LA‐HPI, incorporating four readily obtainable parameters, exhibited superior performance compared to traditional indices.